<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001386</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0622</org_study_id>
    <nct_id>NCT05001386</nct_id>
  </id_info>
  <brief_title>In Vitro Drug Sensitivity Testing of Fresh Human Samples</brief_title>
  <acronym>ESAAC</acronym>
  <official_title>Evaluation of Anti-cancer Drugs Sensitivity on Fresh Samples From Healthy Patients and Patients With Myeloproliferative or Lymphoproliferative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hematological malignancies gather several various pathologies included myeloproliferative&#xD;
      disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and&#xD;
      lymphoproliferative disorders (as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL)&#xD;
      and multiple myeloma (MM)) .&#xD;
&#xD;
      Over the last decade, the treatments have evolved significantly but the overall survival&#xD;
      remains limited, especially for the AML and MM patients. There's an ongoing imperative to&#xD;
      continue in-vitro and in-vivo studies to better evaluate the anti-cancer drugs sensitivity&#xD;
      and therefore improving the response to treatments and open new fields of application. The&#xD;
      healthy control group will be contributing to produce some pertinent and significant data for&#xD;
      the results of the index cases group.&#xD;
&#xD;
      The investigators aim to analyze 10 differents drugs, common use in chemotherapy or&#xD;
      immunotherapy and evaluate by 2 ways the sensitivity: first, Flow cytometry (cells apoptosis&#xD;
      by Annexine V and propidium iodide) on fresh samples and in a second time, monitoring of the&#xD;
      blasts in the mouse's blood after injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the sensitivity of 10 anti-cancer drugs</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Sensitivity determined by in-vitro&#xD;
Tumor cells mortality by Flow cytometry&#xD;
Monitoring of the blasts in the mouse's blood after injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the sensitivity of 10 anti-cancer drugs</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Sensitivity determined by in-vivo fresh samples:</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>Lymphoproliferative disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients followed in the haematology unit of Hospices Civils de Lyon for lymproliferative disorders as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients followed in the medicine of aging unit in the Hospices Civils de Lyon without haematological malignancies, without chemotherapy and without immunosuppressive treatment (≤ 5 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloproliferative disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients followed in the haematology unit of Hospices Civils de Lyon for myeloproliferative disorders as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection for the evaluation of the anti-drugs sensitivity</intervention_name>
    <description>The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Lymphoproliferative disorders</arm_group_label>
    <arm_group_label>Myeloproliferative disorders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Index cases: patients with myeloproliferative or lymphoproliferative disorders.&#xD;
&#xD;
          -  Controls: patients without hematological disease, without chemotherapy ((≤ 5 years.)&#xD;
             and without immunosuppressive treatment at the study time.&#xD;
&#xD;
          -  Age ≥ 18 y.o for all the patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 y.o&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patients deprived of their liberty by judicial or administrative decision.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles Pr DUMONTET, PhD, MD</last_name>
    <phone>0478468340</phone>
    <email>charles.dumontet@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Pr BONNEFOY, MD</last_name>
    <email>marc.bonnefoy@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud -Service d'Hématologie</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charles DUMONTET, MD</last_name>
      <phone>0478468340</phone>
      <email>charles.dumontet@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud -Service de médecine du vieillissement</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc BONNEFOY, MD</last_name>
      <phone>0478861580</phone>
      <email>marc.bonnefoy@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematological malignancies</keyword>
  <keyword>lymphoid</keyword>
  <keyword>myeloid</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>anticancer drugs</keyword>
  <keyword>sensitivity</keyword>
  <keyword>new treatments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

